Involvement of the orexin/hypocretin system in the pharmacological effects induced by Δ(9)-tetrahydrocannabinol
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Flores de los Heros, África, 1985-ca
- dc.contributor.author Julià Hernández, Marinaca
- dc.contributor.author Maldonado, Rafael, 1961-ca
- dc.contributor.author Berrendero Díaz, Fernando, 1971-ca
- dc.date.accessioned 2017-04-24T10:04:04Z
- dc.date.available 2017-04-24T10:04:04Z
- dc.date.issued 2016
- dc.description.abstract BACKGROUND AND PURPOSE: Anatomical, biochemical and pharmacological evidence suggest the existence of a crosstalk between the orexinergic and endocannabinoid systems. While the orexin receptor 1 (OX1 receptor) modulates the reinforcing properties of cannabinoids, the participation of orexins in the acute pharmacological effects of Δ(9) -tetrahydrocannabinol (THC) remains unexplored. EXPERIMENTAL APPROACH: We assessed the possible role of orexins in THC-induced hypolocomotion, hypothermia, antinociception, anxiolytic- and anxiogenic-like effects and memory impairment. Selective OX1 and OX2 receptor antagonists and OX1 knockout (KO) mice as well as prepro-orexin (PPO) KO mice were used as pharmacological and genetic approaches. CB1 receptor levels in control and PPO KO mice were evaluated by immunoblot analysis. The expression of c-Fos after THC treatment was analysed in several brain areas in wild-type mice and in mice lacking the PPO gene. KEY RESULTS: The hypothermia, supraspinal antinociception and anxiolytic-like effects induced by THC were modulated by orexins through OX2 receptor signalling. OX1 receptors did not seem to be involved in these THC responses. No differences in CB1 receptor levels were found between wild-type and PPO KO mice. THC-induced increase in c-Fos expression was reduced in the central amygdala, medial preoptic area and lateral septum in these mutant mice. CONCLUSIONS AND IMPLICATIONS: Our results provide new findings to further clarify the interaction between orexins and cannabinoids. OX1 and OX2 receptors are differently implicated in the pharmacological effects of cannabinoids.
- dc.description.sponsorship This work was supported by the Instituto de Salud Carlos III grants [#PI13/00042 and #RD12/0028/0023 (RTA-RETICS)], by the Spanish Ministry of Science (#SAF2011-29864 and #SAF2014-59648-P), National Plan on Drugs (#2014I019) and the Catalan Government (SGR2014-1547)
- dc.format.mimetype application/pdfca
- dc.identifier.citation Flores Á, Julià-Hernández M, Maldonado R, Berrendero F. Involvement of the orexin/hypocretin system in the pharmacological effects induced by Δ(9) -tetrahydrocannabinol. Br J Pharmacol. 2016 Apr;173(8):1381-92. DOI: 10.1111/bph.13440
- dc.identifier.doi http://dx.doi.org/10.1111/bph.13440
- dc.identifier.issn 0007-1188
- dc.identifier.uri http://hdl.handle.net/10230/30872
- dc.language.iso eng
- dc.publisher Wileyca
- dc.relation.ispartof British Journal of Pharmacology. 2016 Apr;173(8):1381-92
- dc.relation.projectID info:eu-repo/grantAgreement/ES/3PN/SAF2011-29864
- dc.relation.projectID info:eu-repo/grantAgreement/ES/1PE/SAF2014-59648-P
- dc.rights This is the pre-peer reviewed version of the following article: Flores Á, Julià-Hernández M, Maldonado R, Berrendero F. Involvement of the orexin/hypocretin system in the pharmacological effects induced by Δ(9) -tetrahydrocannabinol. Br J Pharmacol. 2016 Apr; 173(8): 1381-92, which has been published in final form at http://dx.doi.org/10.1111/bph.13440. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.subject.other Cannabinoides -- Efectes fisiològics
- dc.subject.other Neuropèptids -- Receptors
- dc.title Involvement of the orexin/hypocretin system in the pharmacological effects induced by Δ(9)-tetrahydrocannabinolca
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/acceptedVersion